State and federal investigators claimed McKesson inflated prices by as much as 25 percent for 1,400 brand-name drugs from 2001 to 2009. This allegedly caused Medicaid programs to pay millions of dollars more in reimbursements.
The drugmaker has denied wrongdoing. A McKesson spokesperson said the claims were without merit but determined a settlement was in the best interest of company employees, customers, suppliers and shareholders, according to the report.
More Articles on Pharmaceutical Companies and Settlements:
Largest Healthcare Settlement in U.S. History: GlaxoSmithKline to Pay $3B
J&J to Pay $2.2B Settlement to End Risperdal Probes
Abbott to Pay $1.5B Settlement for Off-Label Marketing of Depakote
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
